|
|
本帖最后由 normal 于 2011-6-15 23:04 编辑
.
目录
概述........................................................................................................................... 1
个例分析——新化学实体药物...................................................................... 6
1 abiraterone acetate ................................................................................. 6
2 aclidinium bromide ................................................................................ 8
3 apricitabine........................................................................................... 10
4 arbaclofen placarbil.............................................................................. 11
5 CK-1827452......................................................................................... 13
6 delafloxacin.......................................................................................... 17
7 伊多塞班(edoxaban)........................................................................... 19
8 elinogrel ............................................................................................... 21
9 exendin-4, PC-DAC............................................................................. 23
10 fampridine-SR.................................................................................... 24
11 fimasartan........................................................................................... 26
12 fingolimod hydrochloride .................................................................. 28
13 盐酸埃克替尼(icotinib hydrochloride) ............................................ 30
14 IDX-989 ............................................................................................. 32
15 ingenol mebutate................................................................................ 33
16 darapladib........................................................................................... 34
17 laquinimod ......................................................................................... 37
18 LY-2140023........................................................................................ 39
19 migalastat hydrochloride.................................................................... 40
20 ostarine............................................................................................... 42
21 瑞他霉素(retaspimycin) ................................................................... 44
22 ridaforolimus(oral)............................................................................. 47
23 rivoglitazone ...................................................................................... 49
24 romidepsin(fk-228) ............................................................................ 50
25 SLx-2101............................................................................................ 54
26 TC-5619 ............................................................................................. 55
27 telaprevir ............................................................................................ 56
28 TZP-101 ............................................................................................. 58
29 VX-770............................................................................................... 61
个例分析——新生物药物............................................................................ 62
30 albiglutide .......................................................................................... 62
31 afutuzumab......................................................................................... 63
32 阿肽地尔(aviptadil).......................................................................... 64
33 AMG-386 ........................................................................................... 65
34 blinatumomab .................................................................................... 67
35 OTI-010.............................................................................................. 68
36 denosumab ......................................................................................... 70
37 solanezumab....................................................................................... 71
38 teplizumab.......................................................................................... 73
39 曲妥珠单抗-DM1(Trastuzumab-DM1)............................................ 74
40 figitumumab....................................................................................... 75
41 Genz-112638...................................................................................... 76
42 IMGN-901.......................................................................................... 77
43 H5N1 流感疫苗(influenza vaccine H5N1,Novart-8)........................ 78
44 TRU-015 ............................................................................................ 79
个例分析——新剂型药物............................................................................ 82
45 ketorolac, Roxro................................................................................. 82
46 那格列奈+缬沙坦(nateglinide+valsartan) ....................................... 82
47 ostarine............................................................................................... 83
48 芬特明+托吡酯(phentermine+topiramate) ...................................... 85
个例分析——新适应证药物........................................................................ 87
49 富马酸喹硫平(quetiapine fumarate) ................................................ 87
50 曲妥珠单抗(trastuzumab) ................................................................ 88 |
评分
-
查看全部评分
|
[复制链接]
狗仔卡
提升卡
置顶卡
沉默卡
变色卡
抢沙发
千斤顶
显身卡
十个字啊十个字，验证码啊验证码
